Natural killer T cells in health and disease

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 1, 2011, Pages 236-251

  Wu, Lan ^a   Kaer, Luc Van ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD1d; Glycolipid Antigens; Immunomodulation; Immunotherapy; Innate Immunity; Natural killer T cells; Review; Vaccine Adjuvants

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALLERGEN; ALPHA GALACTOSYLCERAMIDE; AUTOANTIGEN; CD150 ANTIGEN; CD1D ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR6; DNA VACCINE; GAMMA INTERFERON; GLYCOSPHINGOLIPID; IMMUNOGLOBULIN A ANTIBODY; INHIBITOR OF DIFFERENTIATION 2; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROGOL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR VACCINE; CYTOKINE; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOTHERAPY; INFECTION; INFLAMMATORY DISEASE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THYMOCYTE; TISSUE GRAFT; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; PHYSIOLOGY; REVIEW;

ADJUVANTS, IMMUNOLOGIC; CYTOKINES; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NATURAL KILLER T-CELLS;

EID: 79955980763     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (170)

1. M. Taniguchi, M. Harada, S. Kojo, T. Nakayama and H. Wakao: The regulatory role of Va14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol., 21, 483-513 (2003) (Pubitemid 37174539)
2. M. Brigl and M. B. Brenner: CD1: antigen presentation and T cell function. Annu. Rev. Immunol., 22, 817-890 (2004) (Pubitemid 38680443)
3. M. Kronenberg: Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol., 26, 877-900 (2005) (Pubitemid 40563188)
4. A. Bendelac, P. B. Savage and L. Teyton: The biology of NKT cells. Annu. Rev. Immunol., 25, 297-336 (2007) (Pubitemid 46697911)
5. L. Van Kaer: NKT cells: T lymphocytes with innate effector functions. Curr. Opin. Immunol., 19(3), 354-364 (2007) (Pubitemid 46687006)
6. D. I. Godfrey, H. R. MacDonald, M. Kronenberg, M. J. Smyth and L. Van Kaer: NK T cells: what's in a name? Nat. Rev. Immunol., 4(3), 231-237 (2004)
7. P. Arrenberg, R. Halder and V. Kumar: Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens. J. Cell. Physiol., 218(2), 246-250 (2009)
8. D. I. Godfrey, S. Stankovic and A. G. Baxter: Raising the NKT cell family. Nat. Immunol., 11(3), 197 -206 (2010)
9. S. K. Mendiratta, W. D. Martin, S. Hong, A. Boesteanu, S. Joyce and L. Van Kaer: CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity, 6(4), 469-477 (1997) (Pubitemid 27208202)
10. Y. H. Chen, N. M. Chiu, M. Mandal, N. Wang and C. R. Wang: Impaired NK1+ T cell development and early IL- 4 production in CD1-deficient mice. Immunity, 6(4), 459-467 (1997) (Pubitemid 27208201)
11. S. T. Smiley, M. H. Kaplan and M. J. Grusby: Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science, 275(5302), 977-979 (1997) (Pubitemid 27087713)
12. A. Bendelac: Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes. J. Exp. Med., 182(6), 2091-2096 (1995)
13. J. S. Bezbradica, T. Hill, A. K. Stanic, L. Van Kaer and S. Joyce: Commitment toward the natural T (iNKT) cell lineage occurs at the CD4+8+ stage of thymic ontogeny. Proc. Natl. Acad. Sci. USA, 102(8), 5114-5119 (2005)
14. T. Egawa, G. Eberl, I. Taniuchi, K. Benlagha, F. Geissmann, L. Hennighausen, A. Bendelac and D. R. Littman: Genetic evidence supporting selection of the Va14i NKT cell lineage from double-positive thymocyte precursors. Immunity, 22(6), 705-716 (2005) (Pubitemid 40814501)
15. C. Borowski and A. Bendelac: Signaling for NKT cell development: the SAP-FynT connection. J. Exp. Med., 201(6), 833-836 (2005) (Pubitemid 40524451)
16. C. S. Ma, K. E. Nichols and S. G. Tangye: Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu. Rev. Immunol., 25, 337-379 (2007) (Pubitemid 46705271)
17. K. Griewank, C. Borowski, S. Rietdijk, N. Wang, A. Julien, D. G. Wei, A. A. Mamchak, C. Terhorst and A. Bendelac: Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. Immunity, 27(5), 751-762 (2007) (Pubitemid 350102258)
18. B. Chung, A. Aoukaty, J. Dutz, C. Terhorst and R. Tan: Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J. Immunol., 174(6), 3153-3157 (2005) (Pubitemid 40354014)
19. K. E. Nichols, J. Hom, S. Y. Gong, A. Ganguly, C. S. Ma, J. L. Cannons, S. G. Tangye, P. L. Schwartzberg, G. A. Koretzky and P. L. Stein: Regulation of NKT cell development by SAP, the protein defective in XLP. Nat. Med., 11, 340-345 (2005) (Pubitemid 40460564)
20. B. Pasquier, L. Yin, M. C. Fondaneche, F. Relouzat , C. Bloch-Queyrat, N. Lambert, A. Fischer, G. de Saint-Basile and S. Latour: Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J. Exp. Med., 201( 5), 695-701 (2005) (Pubitemid 40395115)
21. T. Hu, A. Simmons, J. Yuan, T. P. Bender and J. Alberola-Ila: The transcription factor c-Myb primes CD4+CD8+ immature thymocytes for selection into the iNKT lineage. Nat. Immunol., 11(5), 435- 441 (2010)
22. D. Zhou, J. Mattner, C. Cantu, N. Schrantz, N. Yin, Y. Gao, Y. Sagiv, K. Hudspeth, Y. Wu, T. Yamashita, S. Teneberg, D. Wang, R. Proia, S. B. Levery, P. B. Savage, L. Teyton and A. Bendelac: Lysosomal glycosphingolipid recognition by NKT cells. Science, 306(5702), 1786-1789 (2004) (Pubitemid 39601398)
23. A. K. Stanic, J. S. Bezbradica, J. J. Park, N. Matsuki, A. L. Mora, L. Van Kaer, M. R. Boothby and S. Joyce: NFkappa B controls cell fate specification, survival, and molecular differentiation of immunoregulatory natural T lymphocytes. J. Immunol., 172(4), 2265-2273 (2004) (Pubitemid 38182374)
24. T. Chun, M. J. Page, L. Gapin, J. L. Matsuda, H. Xu, H. Nguyen, H. S. Kang, A. K. Stanic, S. Joyce, W. A. Koltun, M. J. Chorney, M. Kronenberg and C. R. Wang: CD1dexpressing dendritic cells but not thymic epithelial cells can mediate negative selection of NKT cells. J. Exp. Med., 197(7), 907-918 (2003) (Pubitemid 36437867)
25. D. G. Pellicci, A. P. Uldrich, K. Kyparissoudis, N. Y. Crowe, A. G. Brooks, K. J. Hammond, S. Sidobre, M. Kronenberg, M. J. Smyth and D. I. Godfrey: Intrathymic NKT cell development is blocked by the presence of alphagalactosylceramide. Eur. J. Immunol., 33(7), 1816-1823 (2003) (Pubitemid 37120852)
26. D. G. Wei, H. Lee, S. H. Park, L. Beaudoin, L. Teyton, A. Lehuen and A. Bendelac: Expansion and long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes. J. Exp. Med., 202(2), 239-248 (2005) (Pubitemid 41043820)
27. M. I. Zimmer, A. Colmone, K. Felio, H. Xu, A. Ma and C. R. Wang: A cell-type specific CD1d expression program modulates invariant NKT cell development and function. J. Immunol., 176(3), 1421-1430 (2006) (Pubitemid 43134284)
28. I. Engel, K. Hammond, B. A. Sullivan, X. He, I. Taniuchi, D. Kappes and M. Kronenberg: Co-receptor choice by V alpha14i NKT cells is driven by Th-POK expression rather than avoidance of CD8-mediated negative selection. J. Exp. Med., 207(5), 1015- 1029 (2010)
29. L. Gapin: The making of NKT cells. Nat. Immunol., 9(9), 1009-1011 (2008)
30. D. Kovalovsky, O. U. Uche, S. Eladad, R. M. Hobbs, W. Yi, E. Alonzo, K. Chua, M. Eidson, H. J. Kim, J. S. Im, P. P. Pandolfi and D. B. Sant'Angelo: The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat. Immunol., 9(9), 1055-1064 (2008)
31. A. K. Savage, M. G. Constantinides, J. Han, D. Picard, E. Martin, B. Li, O. Lantz and A. Bendelac: The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity, 29(3), 391-403 (2008)
32. J. S. Bezbradica, L. E. Gordy, A. K. Stanic, S. Dragovic, T. Hill, D. Hawiger, D. Unutmaz, L. Van Kaer and S. Joyce: Granulocyte-macrophage colony-stimulating factor regulates effector differentiation of invariant natural killer T cells during thymic ontogeny. Immunity, 25, 487-497 (2006) (Pubitemid 44354212)
33. T. Ranson, C. A. Vosshenrich, E. Corcuff, O. Richard, V. Laloux, A. Lehuen and J. P. Di Santo: IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc. Natl. Acad. Sci. USA, 100(5), 2663-2668 (2003) (Pubitemid 36297555)
34. J. L. Matsuda, L. Gapin, S. Sidobre, W. C. Kieper, J. T. Tan, C. D. Surh and M. Kronenberg: Homeostasis of Va14i NKT cells. Nat. Immunol., 3, 966-974 (2002)
35. F. Geissmann, T. O. Cameron, S. Sidobre, N. Manlongat, M. Kronenberg, M. J. Briskin, M. L. Dustin and D. R. Littman: Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PloS Biol., 3(4), 650-661 (2005)
36. E. Germanov, L. Veinotte, R. Cullen, E. Chamberlain, E. C. Butcher and B. Johnston: Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. J. Immunol., 181(1), 81-91 (2008)
37. T. Ohteki, C. Maki, S. Koyasu, T. W. Mak and P. S. Ohashi: Cutting edge: LFA-1 is req uired for liver NK1.1+TCR alpha beta+ cell development: evidence that liver NK1.1+TCR alpha beta+ cells originate from multiple pathways. J. Immunol., 162(7), 3753-3756 (1999) (Pubitemid 29314748)
38. M. Emoto, H. W. Mittrucker, R. Schmits, T. W. Mak and S. H. Kaufmann: Critical role of leukocyte functionassociated antigen-1 in liver accumulation of CD4+NKT cells. J. Immunol., 162(9), 5094-5098 (1999) (Pubitemid 29307109)
39. L. A. Monticelli, Y. Yang, J. Knell, L. M. D'Cruz, M. A. Cannarile, I. Engel, M. Kronenberg and A. W. Goldrath: Transcriptional regulator Id2 controls survival of hepatic NKT cells. Proc. Natl. Acad. Sci. USA, 106(46), 19461-19466 (2009)
40. B. Wei, G. Wingender, D. Fujiwara, D. Y. Chen, M. McPherson, S. Brewer, J. Borneman, M. Kronenberg and J. Braun: Commensal microbiota and CD8+ T cells shape the formation of invariant NKT cells. J. Immunol., 184(3), 1218-1226 (2010)
41. M. M. Venkataswamy and S. A. Porcelli: Lipid and gly colipid antigens of CD1d-restricted natural killer T cells. Semin. Immunol., 22(2), 68-78 (2010)
42. J. E. Gumperz, C. Roy, A. Makowska, D. Lum, M. Sugita, T. Podrebarac, Y. Koezuka, S. A. Porcelli, S. Cardell, M. B. Brenner and S. M. Behar: Murine CD1drestricted T cell recognition of cellular lipids. Immunity, 12(2), 211-221 (2000) (Pubitemid 30398635)
43. L. M. Fox, D. G. Cox, J. L. Lockridge, X. Wang, X. Chen, L. Scharf, D. L. Trott, R. M. Ndonye, N. Veerapen, G. S. Besra, A. R. Howell, M. E. Cook, E. J. Adams, W. H. Hildebrand and J. E. Gumperz: Recognition of lysophospholipids by human natural killer T lymphocytes. PLoS Biol., 7(10), e1000228 (2009)
44. D. Y. Wu, N. H. Segal, S. Sidobre, M. Kronenberg and P. B. Chapman: Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med., 198(1), 173-181 (2003) (Pubitemid 36870197)
45. K. Fischer, E. Scotet, M. Niemeyer, H. Koebernick, J. Zerrahn, S. Maillet, R. Hurwitz, M. Kursar, M. Bonneville, S. H. E. Kaufmann and U. E. Schaible: Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc. Natl. Acad. Sci. USA, 101(29), 10685-10690 (2004) (Pubitemid 38955803)
46. Y. Kinjo, E. Tupin, D. Wu, M. Fujio, R. Garcia-Navarro, M. Benhnia, D. M. Zajonc, G. Ben-Menachem, G. D. Ainge, G. F. Painter, A. Khurana, K. Hoebe, S. M. Behar, B. Buetler, I. A. Wil son, M. Tsuji, T. J. Sellati, C. H. Wong and M. Kronenberg: Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol., 7(9), 978-986 (2006) (Pubitemid 44263912)
47. J. L. Amprey, J. S. Im, S. J. Turco, H. W. Murray, P. A. Illarionov, G. S. Besra, S. A. Porcelli and G. F. Spath: A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J. Exp. Med., 200(7), 895-904 (2004) (Pubitemid 39362925)
48. H. Lotter, N. Gonzalez-Roldan, B. Lindner, F. Winau, A. Isibasi, M. Moreno-Lafont, A. J. Ulmer, O. Holst, E. Tannich and T. Jacobs: Natu ral killer T cells activated by a lipopeptidophosphoglycan from Entamoeba histolytica are critically important to control amebic liver abscess. PLoS Pathog., 5(5), e1000434 (2009)
49. Y. Kinjo, D. Y. Wu, G. Kim, G.-W. Xing, M. A. Poles, D. D. Ho, M. Tsuji, K. Kawahara, C.-H. Wong and M. Kronenberg: Recognition of bacterial glycosphingolipids by natural killer T cells. Nature, 434(7032), 520-525 (2005) (Pubitemid 40477061)
50. J. Mattner, K. L. DeBord, N. Ismail, R. D. Goff, C. I. Cantu, D. Zhou, P. Saint-Mezard, V. Wang, Y. Gao, N. Yin, K. Hoebe, O. Schneewind, D. Walker, B. Buetler, L. Teyton, P. B. Savage and A. Bendelac: Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature, 434(7032), 525-529 (2005) (Pubitemid 40477062)
51. V. Sriram, W. Du, J. Gervay-Hague and R. R. Brutkiewicz: Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligand for NKT cells. Eur. J. Immunol., 35(6), 1692-1701 (2005) (Pubitemid 40862317)
52. T. Kawano, J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, H. Koseki and M. Taniguchi: CD1d-restricted and TCRmediated activation of Va14 NKT cells by glycosylceramides. Science, 278(5343), 1626-1629 (1997) (Pubitemid 27516282)
53. V. V. Parekh, M. T. Wilson and L. Van Kaer: iNKTcell responses to glycolipids. Crit. Rev. Immunol., 25(3), 183-213 (2005)
54. D. I. Godfrey, D. G. Pellicci, O. Patel, L. Kjer-Nielsen, J. McCluskey and J. Rossjohn: Antigen recognition by CD1d-restricted NKT T cell receptors. Semin. Immunol., 22(2), 61-67 (2010)
55. W. C. Florence, R. K. Bhat and S. Joyce: CD1drestricted glycolipid antigens: presentation principles, recognition logic and functional consequences. Expert. Rev. Mol. Med., 10, e20 (2008)
56. Z. Zeng, A. R. Castano, B. W. Segelke, E. A. Stura, P. A. Peterson and I. A. Wilson: Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science, 277(5324), 339-345 (1997) (Pubitemid 27450700)
57. M. Koch, V. S. Stronge, D. Shepherd, S. D. Gadola, B. Mathew, G. Ritter, A. R. Fersht, G. S. Besra, R. R. Schmidt, E. Y. Jones and V. Cerundolo: The crystal structure of human CD1d with and without agalactosylceramide. Nat. Immunol., 6(8), 819-826 (2005) (Pubitemid 43090468)
58. D. M. Zajonc, C. r. Cantu, J. Mattner, D. Zhou, P. B. Savage, A. Bendelac, I. A. Wilson and L. Teyt on: Structure and function of a potent agonist for the semiinvariant natural killer T cell receptor. Nat. Immunol., 6(8), 810-818 (2005) (Pubitemid 43090467)
59. D. Wu, D. M. Zajonc, M. Fujio, B. A. Sullivan, Y. Kinjo, M. Kronenberg, I. A. Wilson and C. H. Wong: Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc. Natl. Acad. Sci. USA, 103(11), 3972-3977 (2006)
60. D. M. Zajonc, P. B. Savage, A. Bendelac, I. A. Wilson and L. Teyton: Crystal structures of mouse CD1d-iGb3 complex and its cognate Valpha14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. J. Mol. Biol., 377(4), 1104-1116 (2008)
61. D. G. Pellicci, O. Patel, L. Kjer-Nielsen, S. S. Pang, L. C. Sullivan, K. Kyparissoudis, A. G. Brooks, H. H. Reid, S. Gr as, I. S. Lucet, R. Koh, M. J. Smyth, T. Mallevaey, J. L. Matsuda, L. Gapin, J. McCluskey, D. I. Godfrey and J. Rossjohn: Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity, 31(1), 47-59 (2009)
62. N. A. Borg, K. S. Wun, L. Kjer-Nielsen, M. C. Wilce, D. G. Pellicci, R. Koh, G. S. Besra, M. Bharadwaj, D. I. Godfrey, J. McCluskey and J. Rossjohn: CD1d-lipidantigen recognition by the semi-invariant NKT T-cell receptor. Nature, 448(7149), 44-49 (2007) (Pubitemid 47037002)
63. J. P. Scott-Browne, J. L. Matsuda, T. Mallevaey, J. White, N. A. Borg, J. McCluskey, J. Rossjohn, J. Kappler, P. Marrack and L. Gapin: Germline-encoded recognition of diverse glycolipids by natural killer T cells. Nat. Immunol., 8, 1105-1113 (2007) (Pubitemid 47423758)
64. K. S. Wun, N. A. Borg, L. Kjer-Nielsen, T. Beddoe, R. Koh, S. K. Richardson, M. Thakur, A. R. Howell, J. P. Scott-Browne, L. Gapin, D. I. Godfrey, J. McCluskey and J. Rossjohn: A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR. J. Exp. Med., 205(4), 939-949 (2008) (Pubitemid 351549889)
65. T. Mallevaey, J. P. Scott-Browne, J. L. Matsuda, M. H. Young, D. G. Pellicci, O. Patel, M. Thakur, L. Kjer-Nielsen, S. K. Richardson, V. Cerundolo, A. R. Howell, J. McCluskey, D. I. Godfrey, J. Rossjohn, P. Marrack and L. Gapin: T cell re ceptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire. Immunity, 31(1), 60-71 (2009)
66. W. C. Florence, R. K. Bhat and S. Joyce: CD1d-restricted glycol ipid antigens: presentation principles, recognition logic and functional consequences. Expert Rev. Mol. Med., 10, e20 (2008)
67. M. Salio, J. D. Silk and V. Cerundolo: Recent advances in processing a nd presentation of CD1 bound lipid antigens. Curr. Opin. Immunol., 22(1), 81-88 (2010)
68. S. Brozovic, T. Nagaishi, M. Yoshida, S. Betz, A. Salas, D. Chen, A. Kaser, J. Glickman, T. Kuo, A. Little, J. Morrison, N. Corazza, J. Y. Kim, S. P. Colgan, S. G. Young, M. E xley and R. S. Blumberg: CD1d function is regulated by microsomal triglyceride transfer protein. Nat. Med., 10, 535-539 (2004) (Pubitemid 38667914)
69. P. van den Elzen, S. Garg, L. Leon, M. Brigl, E. A. Leadbetter , J. E. Gumperz, C. C. Dascher, T. Y. Cheng, F. M. Sacks, P. A. Illarionov, G. S. Besra, S. C. Kent, D. B. Moody and M. B. Brenner: Apolipoprotein-mediated pathways of lipid antigen presentation. Nature, 437(7060), 906-910 (2005) (Pubitemid 41486768)
70. S. Freigang, V. Zadorozhny, M. K. McKinney, P. Krebs, R. Herro, J. Pawlak, L. Kain, N. Schrantz, K. Masuda, Y. Liu, P. B. Savage, A. Bendelac, B. F. Cravatt and L. Teyton: Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice. J. Clin. Invest., 20(6), 1873- 1884 (2010)
71. T. I. Prigozy, O. Naidenko, P. Qasba, D. Elewaut, L. Brossay, A. Khurana, T. Natori, Y. Koezuka, A. Kulkarni and M. Kronenberg: Glycolipid antigen processing for presentation by CD1d molecules. Science, 291(5504), 664-667 (2001) (Pubitemid 32150427)
72. W. Yuan, X. Qi, P. Tsang, S. J. Kang, P. A. Illarionov, G. S. Besra, J. Gumperz and P. Cresswell: Saposin B is the dominant saposin that facilitates lipid binding to human CD1d molecules. Proc. Natl. Acad. Sci. USA, 104(13), 5551-5556 (2007) (Pubitemid 47175718)
73. N. Schrantz, Y. Sagiv, Y. Liu, P. B. Savage, A. Bendelac and L. Teyton: The Niemann-Pick type C2 protein l oads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells. J. Exp. Med., 204(4), 841-852 (2007) (Pubitemid 46631613)
74. D. Zhou, C. r. Cantu, Y. Sagiv, N. Schrantz, A. B. Kukarni, X. Qi, D. J. Mahuran, C. R. Morales, G. A. Grabowski, K. Benlagha, P. B. Savage, A. Bendelac and L. Teyton: Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science, 303, 523-527 (2004) (Pubitemid 38120850)
75. L. Van Kaer and S. Joyce: Viral evasion of antigen presentation: not just for peptides anymore. Nat. Immunol., 7, 795-797 (2006) (Pubitemid 44084083)
76. K. Kawana, A. J. Quayle, M. Ficarra, J. A. Ibana, L. Sh en, Y. Kawana, H. Yang, L. Marrero, S. Yavagal, S. J. Greene, Y. X. Zhang, R. B. Pyles, R. S. Blumberg and D. J. Schust: CD1d degradation in Chlamydia trachomatisinfected epithelial cells is the result of both cellular and chlamydial proteasomal activity. J. Biol. Chem., 282(10), 7368-7375 (2007) (Pubitemid 47093705)
77. L. Van Kaer and S. Joyce: Innate immunity: NKT cells in the spotlight. Curr. Biol., 15(11), R429-R4 31 (2005) (Pubitemid 40772144)
78. M. Brigl, L. Bry, S. C. Kent, J. E. Gumperz and M. B. Brenner: Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol., 4(12), 1230-1237 (2003) (Pubitemid 37540692)
79. E. Tupin, T. Kinjo and M. Kronenberg: The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol., 5(6), 405-417 (2007) (Pubitemid 46780078)
80. M. Salio, A. O. Speak, D. Shepherd, P. Polzella, P. A. Illarionov, N. Veerapen, G. S. Besra, F. M. Platt and V. Cerundolo: Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc. Natl. Acad. Sci. USA, 104(51), 20490-20495 (2007)
81. C. Paget, T. Mallevaey, A. O. Speak, D. Torres, J. Fontaine, K. C. Sheehan, M. Capron, B. Ryffel, C. Faveeuw, M. Leite de Moraes, F. Platt and F. Trottein: Activation of invariant NKT cells by toll-like receptor 9- stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity, 27(4), 597-609 (2007) (Pubitemid 47628833)
82. K. Muindi, M. Cernadas, G. F. Watts, L. Royle, D. C. Neville, R. A. Dwek, G. S. Besra, P. M. Rudd, T. D. Butters and M. B. Brenner: Activation state and intracellular trafficking contribute to the repertoire of endogenous glycosphingolipids presented by CD1d. Proc. Natl. Acad. Sci. USA, 107(7), 3052 -3057 (2010)
83. G. Raghuraman, Y. Geng and C.-R. Wang: IFN-bmediated up-regulation of CD1d in bacteria-infected APCs. J. Immunol., 177, 7841-7848 (2006) (Pubitemid 44846300)
84. N. A. Nagarajan and M. Kronenberg: Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J. Immunol., 178, 2706-2713 (2007) (Pubitemid 46335652)
85. M. L. Michel, A. C. Keller, C. Paget, M. Fujio, F. Trottein, P. B. Savage, C. H. Wong, E. Schneider, M. Dy and M. C. Leite-de-Moraes: Identification of an IL-17- producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J. Exp. Med., 204(5), 995-1001 (2007) (Pubitemid 46798144)
86. M. T. Wilson, C. Johansson, D. Olivares-Villagomez, A. K. Singh, A. K. Stanic, C. R. Wang, S. Joyce, M. J. Wick and L. Van Kaer: The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad. Sci. USA, 100(19), 10913-10918 (2003) (Pubitemid 37140127)
87. N. Y. Crowe, A. P. Uldrich, K. Kyparissoudis, K. J. L. Hammond, K. Hayakawa, S. Sidobre, R. Keating, M. Kronenberg, M. J. Smyth and D. I. Godfrey: Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J. Immunol., 171(8), 4020-4027 (2003) (Pubitemid 37238677)
88. V. V. Parekh, M. T. Wilson, D. Olivares-Villagomez, A. K. Singh, L. Wu, C.-R. Wang, S. Joyce and L. Van Kaer: Glycolipid antig en induces long-term natural killer T cell anergy in mice. J. Clin. Invest., 115(9), 2572-2583 (2005) (Pubitemid 41266220)
89. A. P. Ulrich, N. Y. Crowe, K. Kyparissoudis, D. G. Pellicci, Y. Zhan, A. M. Lew, P. Bouillet, A. Strasser, M. J. Smyth and D. I. Godfrey: NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol., 175(5), 3092-3101 (2005) (Pubitemid 41170529)
90. V. V. Parekh, A. K. Singh, M. T. Wilson, D. Olivares-Villagomez, J. S. Bezbradica, H. Inazawa, H. Ehara, T. Sakai, I. Serizawa, L. Wu, C. R. Wang, S. Joyce and L. Van Kaer: Quantit ative and qualitative differences in the in vivo response of NKT cells to distinct a- and b-anomeric glycolipids. J. Immunol., 173(6), 3693-3706 (2004) (Pubitemid 39280730)
91. V. V. Parekh, S. Lalani and L. Van Kaer: The in vivo response of invariant natural killer T cells to glycolipid antigens. Int. Rev. Immunol., 26(1-2), 31-48 (2006)
92. J. L. Matsuda, T. Mallevaey, J. Scott-Browne and L. Gapin: CD1d-restricted iNKT cells, the 'Swiss-Army knife'of the immune system. Curr. Opin. Immunol., 20(3), 358-368 (2008)
93. K. Miyamoto, S. Miyake and T. Yamamura: A synthetic glycolipid prevents autoimmune encephalomyelitis by ind ucing TH2 bias of natural killer T cells. Nature, 413(6855), 531-534 (2001) (Pubitemid 32938752)
94. K. O. Yu, J. S. Im, A. Molano, Y. Dutronc, P. A. Illarionov, C. Forestier, N. Fujiwara, I. Arias, S. Miyake, T. Yamamura, Y. T. Chang, G. S. Besra and S. A. Porcelli: Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of a-galactosylceramides. Proc. Natl. Acad. Sci. USA, 102(9), 3383-3388 (2005) (Pubitemid 40328054)
95. J. Schmieg, G. Yang, R. W. Franck and M. Tsuji: Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand a-galactosylceramide. J. Exp. Med., 198(11), 1631-1641 (2003) (Pubitemid 37494156)
96. T. Tashiro, E. Sekine-Kondo, T. Shigeura, R. Nakagawa, S. Inoue, M. Omori-Miyake, T. Chiba, N. Hongo, S. Fujii, K. Shimizu, Y. Yoshiga, T. Sumida, K. Mori, H. Watarai and M. Taniguchi: Induction of Th1- biased cytokine production by alpha-carba-GalCer, a neoglycolipid ligand for NKT cells. Int. Immunol., 22(4), 319 -328 (2010)
97. S. Fujii, K. Shimizu, C. Smith, L. Bonifaz and R. M. Steinman: Activation of natural killer T cells by agalactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered prot ein. J. Exp. Med., 198(2), 267-279 (2003) (Pubitemid 36987852)
98. S. M. Behar and S. A. Porcelli: CD1-restricted T cells in host defense to infectious diseases. Curr. Top. Microbiol. Immunol., 314, 215-250 (2007)
99. E. Tupin, M. R. Benhnia, Y. Kinjo, R. Patsey, C. J. Lena, M. C. Haller, M. J. Caimano, M. Imamura, C. H. Wong, S. Crotty, J. D. Radolf, T. J. Sellati and M. Kronenberg: N KT cells prevent chronic joint inflammation after infection with Borrelia burgdorferi. Proc. Natl. Acad. Sci. USA, 105(50), 19863-19868 (2008)
100. A. G. Joyee, H. Qiu, S. Wang, Y. Fan, L. Bilenki and X. Yang: Distinct NKT cell subsets are induced by different Chlamydia species leading to differential adaptive immunity and host resistance to the infections. J. Immunol., 178(2), 1048-1058 (2007) (Pubitemid 46095178)
101. T. R. Johnson, S. Hong, L. Van Kaer, Y. Koezuka and B. S. Graham: NK T cells contribute to expansion of CD8+ T cells and amplification of antiviral immune responses to respiratory syncytial virus. J. Virol., 76(9), 4294-4303 (2002) (Pubitemid 34309565)
102. D. S. Hansen, M. A. Siomos, L. Buckingham, A. A. Scalzo and L. Schofield: Regulation of murine cerebral malaria pathogenesis by CD1d-restricted NKT cells and the natural killer complex. Immunity, 18(3), 391-402 (2003) (Pubitemid 36351518)
103. E. E. Nieuwenhuis, T. Matsumoto, D. Lindenbergh, R. Willemsen, A. Kaser, Y. Simons-Oosterhuis, S. Brugman, K. Yamaguchi, H. Ish ikawa, Y. Aiba, Y. Koga, J. N. Samsom, K. Oshima, M. Kikuchi, J. C. Escher, M. Hattori, A. B. Onderdonk and R. S. Blumberg: Cd1d-dependent regulation of bacterial colonization in the intestine of mice. J. Clin. Invest., 119(5), 1241-1250 (2009)
104. M. Terabe and J. A. Berzofsky: The role of NKT cells in tumor immunity. Adv. Cancer. Res., 101, 277-348 (2008)
105. L. Wu and L. Van Kaer: Natural killer T cells and autoimmune disease. Curr. Mol. Med., 9(1), 4-14 (2009)
106. C. L. Gabriel, L. Wu, V. V. Parekh and L. Van Kaer: Invariant natural killer T cell-based therapy of autoimmune diseases. Curr. Immunol. Rev., 6, 88- 101 (2010)
107. G. Sireci, D. Russo, F. Dieli, S. A. Porcelli, M. Taniguchi, M. P. La Manna, D. Di Liberto, F. Scarpa and A. Salerno: Immunoregulatory role of Jalpha281 T cells in aged mice developing lupus-like nephritis. Eur. J. Immunol., 37(2), 425-433 (2007) (Pubitemid 46915582)
108. F. Wermeling, S. M. Lind, E. D. Jordo, S. L. Cardell and M. C. Karlsson: Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J. Exp. Med., 207(5), 943-952 (2010)
109. K. Coppieters, P. Dewint, K. Van Beneden, P. Jacques, S. Seeuws, G. Verbruggen, D. Deforce and D. Elewaut: NKT cells: manipulable managers of joint inflammation. Rheumatology, 46(4), 565-571 (2007) (Pubitemid 46523297)
110. Y. H. Chuang, Z. X. Lian, G. X. Yang, S. A. Shu, Y. Moritoki, W. M. Ridgway, A. A. Ansari, M. Kronenberg, R. A. Flavell, B. Gao and M. E. Gershwin: Natural killer T cells exacerbate liver in jury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology, 47(2), 571-580 (2008) (Pubitemid 351280725)
111. J. Mattner, P. B. Savage, P. Leung, S. S. Oertelt, V. Wang, O. Trivedi, S. T. Scanlon, K. Pendem, L. Teyton, J. Hart, W. M. Ridgway, L. S. Wicker, M. E. Gershwin and A. Bendelac: Liver autoimmunity triggered by NKT cells. Cell Host Microbe, 3, 304-315 (2008)
112. S. Joyce and L. Van Kaer: Invariant natural killer T cells trigger adaptive lymphocytes to churn up bile. Cell Host Microbe, 3, 275-277 (2008) (Pubitemid 351636003)
113. O. Akbari, P. Stock, E. Meyer, M. Kronenberg, S. Sidobre, T. Nakayama, M. Taniguchi, M. J. Grusby, R. H. DeKruyff and D. T. Umetsu: Essential role of NKT cells producing IL-4 and IL-13 in the development of allergeninduced airway hyperreactivity. Nat. Med., 9, 582-588 (2003) (Pubitemid 36597105)
114. E. Tupin, A. Nicoletti, R. Elhage, M. Rudling, H. G. Ljunggren, G. K. Hansson and G. P. Berne: CD1d dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med., 199(3), 417-422 (2004) (Pubitemid 38252053)
115. A. S. Major, M. T. Wilson, J. L. McCaleb, Y. Ru Su, A. K. Stanic, S. Joyce, L. Van Kaer, S. Fazio and M. F. Linton: Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol., 24(12), 2351-2357 (2004) (Pubitemid 39658041)
116. Y. Nakai, K. Iw abuchi, S. Fujii, N. Ishimori, N. Dashtsoodol, K. Watano, T. Mishima, C. Iwabuchi, S. Tanaka, J. S. Bezbradica, T. Nakayama, M. Taniguchi, S. Miyake, T. Yamamura, A. Kitabatake, S. Joyce, L. Van Kaer and K. Onoe: Natural killer T cells accelerate atherogenesis in mice. Blood, 104(7), 2051-2059 (2004) (Pubitemid 39297856)
117. R. A. Campos, M. Szczepanik, A. Itakura, M. Akahira-Azuma, S. Sidobre, M. Kronenberg and P. W. Askenase: Cutaneous immunization rapidly activates liver invariant Va14 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact hypersensitivity. J. Exp. Med., 198(12), 1785-1796 (2003) (Pubitemid 38032112)
118. M. I. Zimmer, H. P. Nguyen, B. Wang, H. Xu, A. Colmone, K. Felio, H. J. Choi, P. Zhou, M. L. Alegre and C. R. Wang: Polymorphisms in CD1d affect antigen presentation and the activation of CD1d-restricted T cells. Proc. Natl. Acad. Sci. USA, 106(6), 1909-1914 (2009)
119. F. Heller, I. J. Fuss, E. E. Nieuwenhuis, R. S. Blumberg and W. Strober: Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13- producing NK-T cells. Immunity, 17, 629-638 (2002) (Pubitemid 35351508)
120. K. Takeda, Y. Hayakawa, L. Van Kaer, H. Matsuda, H. Yagita and K. Okumura: Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. USA, 97(10), 5498-5503 (2000) (Pubitemid 30313747)
121. C. M. Lappas, Y. J. Day, M. A. Marshall, V. H. Engelhard and J. Linden: Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med, 203(12), 2639-2648 (2006) (Pubitemid 44833340)
122. K. L. Wallace, M. A. Marshall, S. I. Ramos, J. A. Lannigan, J. J. Field, R. M. Strieter and J. Linden: NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFNgamma and CXCR3 chemokines. Blood, 114(3), 667-676 (2009)
123. K. H. Sonoda, M. Exley, S. Snapper, S. P. Balk and J. Stein-Streilein: CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med., 190(9), 1215-1226 (1999)
124. J. Y. Niederkorn: Role of NKT cells in anterior chamber-associated immune deviation. Expert. Rev. Clin. Immunol., 5(2), 137-144 (2009)
125. K. I. Seino, K. Fukao, K. Muramoto, K. Yanagisawa, Y. Takada, S. Kakuta, Y. Iwakura, L. Van Kaer, K. Takeda, T. Nakayama, M. Taniguchi, H. Bashuda, H. Yagita and K. Okumura: Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc. Natl. Acad. Sci. USA, 98(5), 2577-2581 (2001) (Pubitemid 32209524)
126. A. M. Moodycliffe, D. Nghiem, G. Clydesdale and S. E. Ullrich: Immune suppression and skin cancer development: regulation by NKT cells. Nat. Immunol., 1(6), 521-525 (2000)
127. D. E. Faunce, R. L. Gamelli, M. A. Choudhry and E. J. Kovacs: A role for CD1d-restricted NKT cells in injuryassociated T cell suppression. J Leuk Biol, 73(6), 747-755 (2003) (Pubitemid 38040453)
128. K. Ito, M. Karasawa, T. Kawano, T. Akasaka, H. Koseki, Y. Akutsu, E. Kondo, S. Sekiya, K. Sekikawa, M. Harada, M. Yamashita, T. Nakayama and M. Taniguchi: Involvement of decidual Va14 NKT cells in abortion. Proc. Natl. Acad. Sci. USA, 97(2), 740-744 (2000) (Pubitemid 30070379)
129. A. B. Pillai, T. I. George, S. Dutt, P. Teo and S. Strober: Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J. Immunol., 178(10), 6242-6251 (2007) (Pubitemid 46717407)
130. S. Kim, S. Lalani, V. V. Parekh, L. Wu and L. Van Kaer: Glycolipid
131. V. Cerundolo, J. D. Silk, S. H. Masri and M. Salio: Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol., 9(1), 28-38 (2009)
132. T. S. Devera, H. B. Shah, G. A. Lang and M. L. Lang: Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers. Eur. J. Immunol., 38(4), 1001-1011 (2008)
133. S. Fujii: Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol., 29(5), 242-249 (2008)
134. X. Li, M. Fujio, M. Imamura, D. Wu, S. Vasan, C. H. Wong, D. D. Ho and M. Tsuji: Design of a potent CD1dbinding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci USA, in press
135. G. Gonzalez-Aseguinolaza, L. Van Kaer, C. C. Bergmann, J. M. Wilson, J. Schmieg, M. Kronenberg, T. Nakayama, M. Taniguchi, Y. Koezuka and M. Tsuji: Natural killer T cell ligand a-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med., 195(5), 617-624 (2002) (Pubitemid 34461506)
136. K. Shimizu, Y. Kurosawa, M. Taniguchi, R. M. Steinman and S. Fujii: Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J. Exp. Med., 204(11), 2641-2653 (2007) (Pubitemid 350063944)
137. T. Natori, Y. Koezuka and T. Higa: Agelasp hins, novel a-galactosylceramides from the marine sponge Agelas mauritianus. Tetrahedron Lett., 34(35), 5591-5592 (1993)
138. S. Motohashi and T. Nakayama: Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci., 99(4), 638-645 (2008) (Pubitemid 351448064)
139. S. Fujii, K. Shimizu, M. Kronenberg and R. M. St einman: Prolonged IFN-g-producing NKT response induced with a-galactosylceramide-loaded DCs. Nat. Immunol., 3(9), 867-874 (2002)
140. S. Motohashi, K. Nagato, N. Kunii, H. Yamamoto, K. Yamasaki, K. Okita, H. Hanaoka, N. Shimizu, M. Suzuki, I. Yoshino, M. Taniguchi, T. Fujisawa and T. Nakayama: A phase I-II study of alpha-galactosylceramide-pulsed IL- 2/GM-CSF-cultured peripheral blood mononuclear cells in patien ts with advanced and recurrent non-small cell lung cancer. J. Immunol., 182(4), 2492-2501 (2009)
141. A. M. Woltman, M. J. Ter Borg, R. S. Binda, D. Sprengers, B. M. von Blomberg, R. J. Scheper, K. Hayashi, N. Nishi, A. Boonstra, R. van der Molen and H. L. Janssen: Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir. Ther., 14(6), 809-818 (2009)
142. B. J. Veldt, H. J. van der Vliet, B. M. von Blomberg, H. van Vlierberghe, G. Gerken, N. Nishi, K. Hayashi, R. J. Scheper, R. J. de Knegt, A. J. van den Eertwegh, H. L. Janssen and C. M. van Nieuwkerk: Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J. Hepatol., 47(3), 356-365 (2007) (Pubitemid 47176162)
143. L. Van Kaer: a-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol., 5(1), 31-42 (2005) (Pubitemid 40070329)
144. S. Sharif, G. A. Arreaza, P. Zucker, Q. S. Mi, J. Sond hi, O. V. Naidenko, M. Kronenberg, Y. Koezuka, T. L. Delovitch, J. M. Gombert, M. Leite-De-Moraes, C. Gouarin, R. Zhu, A. Hameg, T. Nakayama, M. Taniguchi, F. Lepault, A. Lehuen, J. F. Bach and A. Herbelin: Activation of natural killer T cells by a-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med., 7(9), 1057-1062 (2001) (Pubitemid 32937388)
145. Y. N. Naumov, K. S. Bahjat, R. Gausling, R. Abraham, M. A. Exley, Y. Koezuka, S. B. Balk, J. L. Strominger, M. Clare-Salzer and S. B. Wilson: Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl. Acad. Sci. USA, 98(24), 13838-13843 (2001) (Pubitemid 33115985)
146. B. Wang, Y. B. Geng and C. R. Wang: CD1-restricted NK T cells protect nonobese diabetic mice from developing diabe tes. J. Exp. Med., 194(3), 313-320 (2001)
147. S. Hong, M. T. Wilson, I. Serizawa, L. Wu, N. Singh, O. V. Naidenko, T. Miura, T. Haba, D. C. Scherer, J. Wei, M. Kronenberg, Y. Koezuka and L. Van Kaer: The natural killer T-cell ligand a-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med., 7(9), 1052-1056 (2001) (Pubitemid 32937387)
148. A. Jahng, I. Maricic, C. Aguilera, S. Cardell, R. C. Halder and V. Kumar: Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med., 199(7), 947-957 (2004) (Pubitemid 38481086)
149. R. Furlan, A. Bergami, D. Cantarella, E. Brambilla, M. Taniguchi, P. Dellabona, G. Casorati and G. Martino: Activation of invariant NKT cells by a-GalCer administration protects mice from MOG35-55 induced EAE: critical roles for administration route and IFN-g. Eur. J. Immunol., 33(7), 1830-1838 (2003) (Pubitemid 37120854)
150. A. K. Singh, M. T. Wilson, S. Hong, D. Olivares-Villagomez, C. Du, A. K. Stanic, S. Joyce, S. Sriram, Y. Koezuka and L. Van Kaer: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med., 194(12), 1801-1811 (2001) (Pubitemid 34028659)
151. J.-Q. Yang, V. Saxena, H. Xu, L. Van Kaer, C. R. Wang and R. R. Singh: Repeated a-galactosylceramide administration results in expansion of Va14 NKT cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J. Immunol., 171(8), 4439-4446 (2003) (Pubitemid 37238724)
152. A. K. Singh, J.-Q. Yang, V. V. Parekh , J. Wei, C.-R. Wang, S. Joyce, R. R. Singh and L. Van Kaer: The natural killer T cell ligand a-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur. J. Immunol., 35(4), 1143-1154 (2005) (Pubitemid 40542221)
153. K. Coppieters, K. Van Beneden, P. Jacques, P. Dewint, A. Vervloet, B. Vander Cruyssen, S. Van Calenbergh, G. Chen, R. W. Franck, G. Verbruggen, D. Deforce, P. Matthys, M. Tsuji, P. Rottiers and D. Elewa ut: A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner. J. Immunol., 179(4), 2300-2309 (2007)
154. A. Miellot, R. Zhu, S. Diem, M. C. Boissier, A. Herbelin and N. Bessis: Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10- dependent pathway. Eur. J. Immunol., 35(12), 3704-3713 (2005) (Pubitemid 43025550)
155. R. Liu, A. La Cava, X.-F. Bai, Y.-h. Jee, M. Price, D. I. Campagnolo, P. Christadoss, T. L. Vollmer, L. Van Kaer and F.-D. Shi: Cooperation of invariant NKT cells and CD4+CD25+ regulatory T cells in the prevention of autoimmune myasthenia. J. Immunol., 175(12), 7898-7904 (2005) (Pubitemid 41798350)
156. Y. Nagayama, K. Watanabe, M. Niwa, S. M. McLachlan and B. Rapoport: Schistosoma mansoni and agalactosylceramide : prophylactic effect of Th1 immune suppression in a mouse model of Graves' hyperthyroidism. J. Immunol., 173(3), 2167-2173 (2004) (Pubitemid 38971656)
157. R. S. Grajewski, A. M. Hansen, R. K. Agarwal, M. Kronenberg, S. Sidobre, S. B. Su, P. B. Silver, M. Tsuji, R. W. Franck, A. P. Lawton, C. C. Chan and R. R. Caspi: Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN- gamma production and dampening of the adaptive Th1 and Th17 responses. J. Immunol., 181(7), 4791-4797 (2008)
158. J. P. Driver, F. Scheuplein, Y. G. Chen, A. E. Grier, S. B. Wilson and D. V. Serreze: Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette. Diabetes, 59(2), 423- 432 (2010)
159. A. W. Jahng, I. Maricic, B. Pedersen, N. Burdin, O. Naidenko, M. Kronenberg, Y. Koezuka and V. Kumar: Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med., 194(12), 1789-1799 (2001) (Pubitemid 34028658)
160. D. Zeng, Y. Liu, S. Sidobre, M. Kronenberg and S. Strober: Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J. Clin. Invest., 112(8), 1211-1222 (2003) (Pubitemid 38056298)
161. H. Y. Kim, H. J. Kim, H. S. Min, S. Kim, W. S. Park, S. H. Park and D. H. Chung: NKT cells promote antibodyinduced joint inflammation by suppressing transforming growth factor beta1 production. J. Exp. Med., 201(1), 41-47 (2005) (Pubitemid 40130082)
162. D. Hashimoto, S. Asakura, S. Miyake, T. Yamamura, L. Van Kaer, C. Liu, M. Tanimoto and T. Teshima: Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J. Immunol., 174(1), 551-556 (2005) (Pubitemid 40007446)
163. K. Haraguchi, T. Takahashi, A. Matsumoto, T. Asai, Y. Kanda, M. Kurokawa, S. Ogawa, H. Oda, M. Taniguchi, H. Hirai and S. Chiba: Host-residual invariant NK T cells attenuate graft-versus-host immunity. J. Immunol., 175(2), 1320-1328 (2005) (Pubitemid 41095022)
164. R. D. Kuns, E. S. Morris, K. P. Macdonald, K. A. Markey, H. M. Morris, N. C. Raffelt, T. Banovic, A. L. Don, V. Rowe, A. C. Burman, A. D. Clouston, C. Farah, G. S. Besra, P. A. Illarionov, M. J. Smyth, S. A. Porcelli and G. R. Hill: Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alphagalactosylceramide administration. Blood, 113(23), 5999-6010 (2009)
165. Y. Ueno, S. Tanaka, M. Sumii, S. Miyake, S. Tazuma, M. Taniguchi, T. Yamamura and K. Chayama: Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of Va14 natural killer T cells in mice. Infl. Bow. Dis., 11(1), 35-41 (2005) (Pubitemid 40340254)
166. L. J. Saubermann, P. Beck, Y. P. De Jong, R. S. Pitman, M. S. Ryan, H. S. Kim, M. Exley, S. Snapper, S. P. Balk, S. J. Hagen, O. Kanauchi, K. Motoki, T. Sakai, C. Terhorst, Y. Koezuka, D. K. Podolsky and R. S. Blumberg: Activation of natural killer T cells by a-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterol., 119(1), 119-128 (2000) (Pubitemid 30452585)
167. N. A. Braun, R. Covarrubias and A. S. Major: Natural killer T cells and atherosclerosis: form and function meet pathogenesis. J. Innate Immun., 2(4), 316-324 (2010)
168. G. H. van Puijvelde, E. J. van Wanrooij, A. D. Hauer, P. de Vos, T. J. van Berkel and J. Kuiper: Effect of natural killer T cell activation on the initiation of atherosclerosis. Thromb. Haemost., 102(2), 223-230 (2009)
169. E. H. Meyer, R. H. DeKruyff and D. T. Umetsu: iNKT cells in allergic disease. Curr. Top. Microbiol. Immunol., 314, 269-291 (2007)
170. V. Lombardi, P. Stock, A. K. Singh, J. Kerzerho, W. Yang, B. A. Sullivan, X. Li, T. Shiratsuchi, N. E. Hnatiuk, A. R. Howell, K. O. Yu, S. A. Porcelli, M. Tsuji, M. Kronenberg, S. B. Wilson and O. Akbari: A CD1ddependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J. Immunol., 184(4), 2107 -2115 (2010)